Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments. Virus Genes 2009 Apr;38(2):195-203
Date
01/14/2009Pubmed ID
19139983DOI
10.1007/s11262-008-0325-yScopus ID
2-s2.0-61849139074 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.
Author List
Arav-Boger RAuthor
Ravit Boger MD Chief, Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Angiogenesis InhibitorsAntiviral Agents
Herpesvirus 8, Human
Humans
Immunologic Factors
Sarcoma, Kaposi